Plus Therapeutics Announces Presentation of Data from the ReSPECT-GBM Trial and Plans for Treating Pediatric Brain Cancer (GlobeNewswire) - Aug 21, 2021 - P1, N=55; ReSPECT (NCT01906385); Sponsor: Plus Therapeutics; "Plus Therapeutics, Inc...presented data from the NIH-supported ReSPECTTM Phase 1 clinical trial evaluating its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma (GBM)...This data is being presented as an E-Poster video...at the 2021 American Association of Neurological Surgeons (AANS) Annual Scientific Meeting, which is being held virtually August 21-25, 2021...Additional key findings from ReSPECT™ clinical trial for adult recurrent GBM: The mean dose of 186RNL when coverage was 75% or greater (n=10) was 392 Gy (CI 306 – 478). The treatment has been well tolerated, with no dose-limiting toxicity or serious adverse events observed (n=18)."
P1 data • Brain Cancer • Glioblastoma • Oncology
|